Schwab Andrew J. — SEC insider filings
SEC reporting owner CIK 1598549. 73 insider filings on record with FilingPulse; latest filed 2026-09-24.
Transaction summary — filings shown
Covers the 50 most recent of 73 filings on record, filed 2022-05-25 to 2026-09-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 3 filings — 2,342,423 shares, $37,999,986 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 101 legs across 28 filings — 23,749,606 shares, $52,648,043 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 44.
- Largest priced transaction: purchase of 487,333 shares @ $30.00 ($14,619,990) in CinCor Pharma, Inc., filed 2022-08-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | 10% owner | 6 | — | 8 legs · 1,962,500 sh · $29,795,000 | 3 |
| CinCor Pharma, Inc. (CINC) | 10% owner | 2 | 2 legs · 600,000 sh · $18,000,000 | — | 3 |
| Camp4 Therapeutics Corp (CAMP) | Director | 8 | 1 leg · 909,090 sh · $9,999,990 | 5 legs · 591,875 sh · $2,495,764 | 10 |
| Artiva Biotherapeutics, Inc. (ARTV) | 10% owner | 1 | 1 leg · 833,333 sh · $9,999,996 | — | 5 |
| Pear Therapeutics, Inc. (PEAR) | 10% owner | 6 | — | 33 legs · 18,431,771 sh · $5,712,873 | — |
| Entrada Therapeutics, Inc. (TRDA) | 10% owner | 5 | — | 13 legs · 531,285 sh · $4,068,043 | — |
| Rallybio Corp (RLYB) | 10% owner | 3 | — | 5 legs · 350,000 sh · $3,995,000 | — |
| scPharmaceuticals Inc. (SCPH) | 10% owner | 2 | — | 12 legs · 826,622 sh · $3,585,860 | — |
| Skye Bioscience, Inc. (SKYE) | Director, 10% owner | 15 | — | 25 legs · 1,055,553 sh · $2,995,503 | 15 |
| Latigo Biotherapeutics, Inc. (LTGO) | 10% owner | 1 | — | — | 6 |
+1 more issuer among the filings shown — every filing appears in the table below.
Insider filings — Schwab Andrew J.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-24 | 4 | Skye Bioscience, Inc. (SKYE) | Sale (S): 27,612 @ $1.65 · Sale (S): 1,088 @ $1.65 · Sale (S): 114,851 @ $1.61 · Sale (S): 4,528 @ $1.61 | EDGAR |
| 2026-09-18 | 4 | Skye Bioscience, Inc. (SKYE) | Sale (S): 32,607 @ $1.91 · Sale (S): 1,285 @ $1.91 | EDGAR |
| 2026-08-31 | 4 | Camp4 Therapeutics Corp (CAMP) | Sale (S): 400,000 @ $4.04 | EDGAR |
| 2026-08-26 | 4 | Camp4 Therapeutics Corp (CAMP) | Sale (S): 10 @ $4.50 | EDGAR |
| 2026-08-21 | 4 | Camp4 Therapeutics Corp (CAMP) | Sale (S): 45,147 @ $4.76 · Sale (S): 114,700 @ $4.54 · Sale (S): 32,018 @ $4.50 | EDGAR |
| 2026-08-20 | 4 | Skye Bioscience, Inc. (SKYE) | Sale (S): 45,090 @ $0.38 · Sale (S): 1,830 @ $0.38 · Sale (S): 253,080 @ $0.38 · Sale (S): 10,255 @ $0.35 · Sale (S): 409 @ $0.35 · Sale (S): 57,476 @ $0.35 · +3 more | EDGAR |
| 2026-08-12 | 4 | Latigo Biotherapeutics, Inc. (LTGO) jointly with 5AM Ventures VI, L.P., 5AM Partners VI, LLC, 5AM Opportunities II, L.P., 5AM Opportunities II (GP), LLC, PARMAR KUSH | Conversion (C): 4,975,543 · Conversion (C): 2,350,419 · Conversion (C): 3,152,305 (derivative) @ $0 · Conversion (C): 1,823,238 (derivative) @ $0 · Conversion (C): 866,018 (derivative) @ $0 · Conversion (C): 1,484,401 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, ROCKLAGE SCOTT M | Sale (S): 10,494 @ $7 · Sale (S): 52,317 @ $6.85 | EDGAR |
| 2026-08-05 | 4 | Camp4 Therapeutics Corp (CAMP) | Grant/award (A): 3,179,558 (derivative) @ $1.53 | EDGAR |
| 2026-08-03 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, ROCKLAGE SCOTT M | Sale (S): 114,756 @ $6.93 · Sale (S): 1,718 @ $6.85 | EDGAR |
| 2026-06-12 | 4 | Camp4 Therapeutics Corp (CAMP) | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-11-18 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, ROCKLAGE SCOTT M | Sale (S): 200,000 @ $8.80 | EDGAR |
| 2025-09-15 | 4 | Camp4 Therapeutics Corp (CAMP) | Grant/award (A): 2,941,176 @ $1.53 | EDGAR |
| 2025-08-22 | 4 | Skye Bioscience, Inc. (SKYE) | Sale (S): 58,642 @ $3.57 · Sale (S): 2,314 @ $3.57 · Sale (S): 163,979 @ $3.42 · Sale (S): 6,470 @ $3.42 | EDGAR |
| 2025-07-11 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, ROCKLAGE SCOTT M | Sale (S): 20,065 @ $7.50 · Sale (S): 6,935 @ $7.50 | EDGAR |
| 2025-07-01 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, ROCKLAGE SCOTT M | Sale (S): 55,735 @ $6.91 · Sale (S): 19,265 @ $6.91 · Sale (S): 18,578 @ $6.81 · Sale (S): 6,422 @ $6.81 · Sale (S): 18,578 @ $7.12 · Sale (S): 6,422 @ $7.12 | EDGAR |
| 2025-06-27 | 4 | Camp4 Therapeutics Corp (CAMP) | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2024-10-30 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | Camp4 Therapeutics Corp (CAMP) | Conversion (C): 1,337,592 · Conversion (C): 378,463 · Conversion (C): 302,770 · Purchase (P): 909,090 @ $11 · Conversion (C): 15,002,166 (derivative) · Conversion (C): 4,244,770 (derivative) · +1 more | EDGAR |
| 2024-09-13 | 4 | Skye Bioscience, Inc. (SKYE) | Sale (S): 214,556 @ $6.60 · Sale (S): 36,504 @ $6.60 · Sale (S): 1,440 @ $6.60 · Sale (S): 11,758 @ $6.06 · Sale (S): 2,000 @ $6.06 · Sale (S): 79 @ $6.06 | EDGAR |
| 2024-07-24 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P., PARMAR KUSH | Conversion (C): 1,058,284 · Other (J): 112,966 @ $10.20 · Other (J): 348,721 @ $10.20 · Purchase (P): 833,333 @ $12 · Conversion (C): 843,592 (derivative) · Conversion (C): 214,692 (derivative) | EDGAR |
| 2024-03-15 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 450,000 @ $10 | EDGAR |
| 2024-03-04 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., PARMAR KUSH | Sale (S): 688,358 @ $14.90 · Sale (S): 136,642 @ $14.90 | EDGAR |
| 2024-02-02 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 5,206,074 @ $2.31 | EDGAR |
| 2024-02-02 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., PARMAR KUSH | Sale (S): 417,187 @ $15 · Sale (S): 82,813 @ $15 | EDGAR |
| 2023-11-06 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 14,110 (derivative) @ $0 | EDGAR |
| 2023-09-28 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., PARMAR KUSH | Sale (S): 164,789 @ $15 · Sale (S): 32,711 @ $15 | EDGAR |
| 2023-08-29 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 1,472,692 (derivative) @ $0 | EDGAR |
| 2023-08-28 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., PARMAR KUSH | Sale (S): 367,124 @ $16 · Sale (S): 72,876 @ $16 | EDGAR |
| 2023-08-22 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 267,602,039 · Grant/award (A): 10,558,878 · Grant/award (A): 684,361,447 @ $0.01 · Grant/award (A): 161,944,872 @ $0.01 · Grant/award (A): 6,389,921 @ $0.01 · Grant/award (A): 426,348,120 (derivative) @ $0 | EDGAR |
| 2023-04-12 | 4 | Pear Therapeutics, Inc. (PEAR) jointly with 5AM Partners IV, LLC, 5AM Ventures IV, L.P., 5AM Co-Investors IV, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 12,836,489 @ $0.12 · Sale (S): 534,855 @ $0.12 · Sale (S): 3,172,769 @ $0.12 | EDGAR |
| 2023-04-06 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 27,567 (derivative) @ $0 | EDGAR |
| 2023-03-09 | 4 | Rallybio Corp (RLYB) jointly with 5AM Partners V, LLC, 5AM Ventures V, L.P., ROCKLAGE SCOTT M | Sale (S): 100,000 @ $8.20 | EDGAR |
| 2023-02-28 | 4 | CinCor Pharma, Inc. (CINC) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I, L.P., PARMAR KUSH, 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P., 5AM Opportunities I (GP), LLC | Code (U): 3,953,990 · Code (U): 487,333 · Code (U): 496,323 | EDGAR |
| 2023-02-27 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 4,838,092 · Grant/award (A): 960,383 | EDGAR |
| 2022-12-02 | 4 | Akouos, Inc. (AKUS) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, ROCKLAGE SCOTT M | Code (U): 3,153,333 · Code (U): 982,453 | EDGAR |
| 2022-11-15 | 4 | Pear Therapeutics, Inc. (PEAR) jointly with 5AM Partners IV, LLC, 5AM Ventures IV, L.P., 5AM Co-Investors IV, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 28,205 @ $3.19 · Sale (S): 1,175 @ $3.19 · Sale (S): 11,643 @ $2.79 · Sale (S): 485 @ $2.79 · Sale (S): 61,222 @ $2.52 · Sale (S): 2,551 @ $2.52 | EDGAR |
| 2022-11-02 | 4 | Pear Therapeutics, Inc. (PEAR) jointly with 5AM Partners IV, LLC, 5AM Ventures IV, L.P., 5AM Co-Investors IV, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 40,477 @ $2.78 · Sale (S): 1,687 @ $2.78 · Sale (S): 1,408 @ $2.80 · Sale (S): 59 @ $2.80 · Sale (S): 10,155 @ $2.72 · Sale (S): 423 @ $2.72 | EDGAR |
| 2022-10-11 | 4 | scPharmaceuticals Inc. (SCPH) jointly with 5AM Partners IV, LLC, 5AM Co-Investors IV, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., 5AM Ventures IV, L.P., DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 30,457 @ $5.02 · Sale (S): 1,269 @ $5.02 · Sale (S): 5,808 @ $5.02 · Sale (S): 456,413 @ $4.09 · Sale (S): 19,017 @ $4.09 · Sale (S): 87,036 @ $4.09 | EDGAR |
| 2022-09-16 | 4 | Pear Therapeutics, Inc. (PEAR) jointly with 5AM Partners IV, LLC, 5AM Ventures IV, L.P., 5AM Co-Investors IV, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 273,664 @ $1.94 · Sale (S): 11,403 @ $1.94 · Sale (S): 261,840 @ $1.81 · Sale (S): 10,910 @ $1.81 · Sale (S): 337 @ $1.75 · Sale (S): 14 @ $1.75 | EDGAR |
| 2022-09-08 | 4 | scPharmaceuticals Inc. (SCPH) jointly with 5AM Partners IV, LLC, 5AM Co-Investors IV, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., 5AM Ventures IV, L.P., DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 21,702 @ $5.52 · Sale (S): 904 @ $5.52 · Sale (S): 4,016 @ $5.52 · Sale (S): 163,034 @ $4.75 · Sale (S): 6,793 @ $4.75 · Sale (S): 30,173 @ $4.75 | EDGAR |
| 2022-09-08 | 4 | Pear Therapeutics, Inc. (PEAR) jointly with 5AM Partners IV, LLC, 5AM Ventures IV, L.P., 5AM Co-Investors IV, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 298,714 @ $2.36 · Sale (S): 12,446 @ $2.36 · Sale (S): 148,337 @ $1.92 · Sale (S): 6,181 @ $1.92 · Sale (S): 292,149 @ $1.81 · Sale (S): 12,173 @ $1.81 | EDGAR |
| 2022-08-18 | 4 | Pear Therapeutics, Inc. (PEAR) jointly with 5AM Partners IV, LLC, 5AM Ventures IV, L.P., 5AM Co-Investors IV, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 160,476 @ $1.78 · Sale (S): 6,686 @ $1.78 · Sale (S): 9,674 @ $1.71 · Sale (S): 403 @ $1.71 · Sale (S): 213,851 @ $1.55 · Sale (S): 8,910 @ $1.55 | EDGAR |
| 2022-08-17 | 4 | CinCor Pharma, Inc. (CINC) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., PARMAR KUSH, 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P. | Purchase (P): 112,667 @ $30 · Purchase (P): 487,333 @ $30 | EDGAR |
| 2022-06-07 | 4 | Rallybio Corp (RLYB) jointly with 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, 5AM Partners V, LLC, 5AM Ventures V, L.P., ROCKLAGE SCOTT M | Sale (S): 50,329 @ $12.50 · Sale (S): 99,671 @ $12.50 | EDGAR |
| 2022-05-25 | 4 | Rallybio Corp (RLYB) jointly with 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, 5AM Partners V, LLC, 5AM Ventures V, L.P., ROCKLAGE SCOTT M | Sale (S): 33,553 @ $13 · Sale (S): 66,447 @ $13 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1598549 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs